Fort Washington Investment Advisors Inc. OH Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Fort Washington Investment Advisors Inc. OH reduced its stake in Gilead Sciences by 99.4% in the second quarter, holding only 1,934 shares after selling 307,957 shares.
• Gilead Sciences reported earnings of $2.01 EPS for the last quarter, exceeding analyst expectations, with revenues reaching $7.08 billion.
• In the last three months, insiders sold a total of 72,000 shares of Gilead stock, worth approximately $8.29 million.

Fort Washington Investment Advisors Inc. OH cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 99.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,934 shares of the biopharmaceutical company's stock after selling 307,957 shares during the period. Fort Washington Investment Advisors Inc. OH's holdings in Gilead Sciences were worth $214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth $620,415,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC grew its holdings in shares of Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock valued at $282,706,000 after purchasing an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Trading Up 0.5%

Shares of NASDAQ GILD opened at $112.62 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $139.74 billion, a PE ratio of 22.43, a PEG ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a twelve month low of $82.82 and a twelve month high of $121.83. The stock has a fifty day simple moving average of $114.50 and a 200-day simple moving average of $109.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. UBS Group lifted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Finally, Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $117.17.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company's stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,000 shares of company stock worth $8,285,530 in the last ninety days. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.